Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06000423
PHASE4

Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects

Sponsor: Oregon Health and Science University

View on ClinicalTrials.gov

Summary

This randomized double blinded trial seeks to determine whether tranexamic acid (TXA) is an efficacious treatment for contraceptive induced menstrual changes (CIMC) including irregular, bothersome bleeding caused by the etonogestrel subdermal contraceptive implant (ENG implant). Participants will be randomized into the TXA treatment arm or a placebo. They will begin taking the medication after three consecutive days of bleeding. Participants will track their bleeding using an automated text message service

Key Details

Gender

FEMALE

Age Range

15 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

65

Start Date

2024-01-23

Completion Date

2025-08-14

Last Updated

2026-10-15

Healthy Volunteers

No

Interventions

DRUG

Tranexamic acid

1300mg TXA taken three times per day for five days

OTHER

Placebo

Placebo pills taken three times daily for five days.

Locations (1)

Oregon Health & Science University

Portland, Oregon, United States